Low-distortion slow light using two absorption resonances

We consider group delay and broadening using two strongly absorbing and widely spaced resonances. We derive relations which show that very large pulse bandwidths coupled with large group delays and small broadening can be achieved. Unlike single resonance systems, the dispersive broadening dominates the absorptive broadening which leads to a dramatic increase in the possible group delay. We show that the double resonance systems are excellent candidates for realizing all-optical delay lines. We report on an experiment which achieved up to 50 pulse delays with 40% broadening.Comment: 4 pages 4 figure

Slow Light with Large Fractional Delays By Spectral Hole-Burning in Rubidium Vapor

We report on the experimental realization of large fractional pulse delays in a hot, Doppler-broadened rubidium vapor. A pump laser burns a deep spectral hole in the inhomogeneously broadened vapor. The delay is shown to be widely tunable by both power broadening the resonance and frequency modulating the pump laser. The simplicity of the scheme opens up the possibility for practical optical delays and buffers

Low-Distortion Slow Light Using Two Absorption Resonances

We consider group delay and broadening using two strongly absorbing and widely spaced resonances. We derive relations which show that very large pulse bandwidths coupled with large group delays and small broadening can be achieved. Unlike single resonance systems, the dispersive broadening dominates the absorptive broadening which leads to a dramatic increase in the possible group delay. We show that the double resonance systems are excellent candidates for realizing all-optical delay lines. We report on an experiment which achieved up to 50 pulse delays with 40% broadening

Wide-bandwidth, tunable, multiple-pulse-width optical delays using slow light in cesium vapor

We demonstrate an all-optical delay line in hot cesium vapor that tunably delays 275 ps input pulses up to 6.8 ns and 740 input ps pulses up to 59 ns (group index of approximately 200) with little pulse distortion. The delay is made tunable with a fast reconfiguration time (hundreds of ns) by optically pumping out of the atomic ground states.Comment: 4 pages, 6 figure

Wide-Bandwidth, Tunable, Multiple-Pulse-Width Optical Delays Using Slow Light in Cesium Vapor

We demonstrate an all-optical delay line in hot cesium vapor that tunably delays 275 ps input pulses up to 6.8 ns and 740 input ps pulses up to 59 ns (group index of approximately 200) with little pulse distortion. The delay is made tunable with a fast reconfiguration time (hundreds of ns) by optically pumping out of the atomic ground states

Mutation of the Zebrafish Nucleoporin elys Sensitizes Tissue Progenitors to Replication Stress

The recessive lethal mutation flotte lotte (flo) disrupts development of the zebrafish digestive system and other tissues. We show that flo encodes the ortholog of Mel-28/Elys, a highly conserved gene that has been shown to be required for nuclear integrity in worms and nuclear pore complex (NPC) assembly in amphibian and mammalian cells. Maternal elys expression sustains zebrafish flo mutants to larval stages when cells in proliferative tissues that lack nuclear pores undergo cell cycle arrest and apoptosis. p53 mutation rescues apoptosis in the flo retina and optic tectum, but not in the intestine, where the checkpoint kinase Chk2 is activated. Chk2 inhibition and replication stress induced by DNA synthesis inhibitors were lethal to flo larvae. By contrast, flo mutants were not sensitized to agents that cause DNA double strand breaks, thus showing that loss of Elys disrupts responses to selected replication inhibitors. Elys binds Mcm2-7 complexes derived from Xenopus egg extracts. Mutation of elys reduced chromatin binding of Mcm2, but not binding of Mcm3 or Mcm4 in the flo intestine. These in vivo data indicate a role for Elys in Mcm2-chromatin interactions. Furthermore, they support a recently proposed model in which replication origins licensed by excess Mcm2-7 are required for the survival of human cells exposed to replication stress

The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review

Background: The presence of circulating cell-free DNA from tumours in blood (ctDNA) is of major importance to those interested in early cancer detection, as well as to those wishing to monitor tumour progression or diagnose the presence of activating mutations to guide treatment. In 2014, the UK Early Cancer Detection Consortium undertook a systematic mapping review of the literature to identify blood-based biomarkers with potential for the development of a non-invasive blood test for cancer screening, and which identified this as a major area of interest. This review builds on the mapping review to expand the ctDNA dataset to examine the best options for the detection of multiple cancer types. Methods: The original mapping review was based on comprehensive searches of the electronic databases Medline, Embase, CINAHL, the Cochrane library, and Biosis to obtain relevant literature on blood-based biomarkers for cancer detection in humans (PROSPERO no. CRD42014010827). The abstracts for each paper were reviewed to determine whether validation data were reported, and then examined in full. Publications concentrating on monitoring of disease burden or mutations were excluded. Results: The search identified 94 ctDNA studies meeting the criteria for review. All but 5 studies examined one cancer type, with breast, colorectal and lung cancers representing 60% of studies. The size and design of the studies varied widely. Controls were included in 77% of publications. The largest study included 640 patients, but the median study size was 65 cases and 35 controls, and the bulk of studies (71%) included less than 100 patients. Studies either estimated cfDNA levels non-specifically or tested for cancer-specific mutations or methylation changes (the majority using PCR-based methods). Conclusion: We have systematically reviewed ctDNA blood biomarkers for the early detection of cancer. Pre-analytical, analytical, and post-analytical considerations were identified which need to be addressed before such biomarkers enter clinical practice. The value of small studies with no comparison between methods, or even the inclusion of controls is highly questionable, and larger validation studies will be required before such methods can be considered for early cancer detection

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

Background The risk factors for recovery from COVID-19 dyspnoea are poorly understood. We investigated determinants of recovery from dyspnoea in adults with COVID-19 and compared these to determinants of recovery from non-COVID-19 dyspnoea. Methods We used data from two prospective cohort studies: PHOSP-COVID (patients hospitalised between March 2020 and April 2021 with COVID-19) and COVIDENCE UK (community cohort studied over the same time period). PHOSP-COVID data were collected during hospitalisation and at 5-month and 1-year follow-up visits. COVIDENCE UK data were obtained through baseline and monthly online questionnaires. Dyspnoea was measured in both cohorts with the Medical Research Council Dyspnoea Scale. We used multivariable logistic regression to identify determinants associated with a reduction in dyspnoea between 5-month and 1-year follow-up. Findings We included 990 PHOSP-COVID and 3309 COVIDENCE UK participants. We observed higher odds of improvement between 5-month and 1-year follow-up among PHOSP-COVID participants who were younger (odds ratio 1.02 per year, 95% CI 1.01–1.03), male (1.54, 1.16–2.04), neither obese nor severely obese (1.82, 1.06–3.13 and 4.19, 2.14–8.19, respectively), had no pre-existing anxiety or depression (1.56, 1.09–2.22) or cardiovascular disease (1.33, 1.00–1.79), and shorter hospital admission (1.01 per day, 1.00–1.02). Similar associations were found in those recovering from non-COVID-19 dyspnoea, excluding age (and length of hospital admission). Interpretation Factors associated with dyspnoea recovery at 1-year post-discharge among patients hospitalised with COVID-19 were similar to those among community controls without COVID-19. Funding PHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19. The views expressed in the publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care. COVIDENCE UK is supported by the UK Research and Innovation, the National Institute for Health Research, and Barts Charity. The views expressed are those of the authors and not necessarily those of the funders

Between Commerce and Empire: David Hume, Colonial Slavery, and Commercial Incivility

Eighteenth-century Enlightenment thought has recently been reclaimed as a robust, albeit short-lived, cosmopolitan critique of European imperialism. This essay complicates this interpretation through a study of David Hume’s reflections on commerce, empire and slavery. I argue that while Hume condemned the colonial system of monopoly, war and conquest, his strictures against empire did not extend to colonial slavery in the Atlantic. This was because colonial slavery represented a manifestly uncivil institution when judged by enlightened metropolitan sensibilities, yet also a decisively commercial institution pivotal to the eighteenth-century global economy. Confronted by the paradoxical ‘commercial incivility’ of modern slavery, Hume opted for disavowing the link between slavery and commerce, and confined his criticism of slavery to its ancient, feudal and Asiatic incarnations. I contend that Hume’s disavowal of the commercial barbarism of the Atlantic economy is part of a broader ideological effort to separate the idea of commerce from its imperial origins and posit it as the liberal antithesis of empire. The implications of analysis, I conclude, go beyond the eighteenth-century debates over commerce and empire, and more generally pertain to the contradictory entwinement of liberalism and capitalism